Pharming Group N.V.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PHAR | LXRX | PHVS | BHVN | B9A.F | PRTA | |
|---|---|---|---|---|---|---|
| Market cap | 881.90M | 658.53M | 2.41B | 2.30B | 2.45B | 430.72M |
| P/E (TTM) | 38.9 | — | — | — | 250.7 | — |
| Forward P/E | 69.2 | -7.8 | -11.2 | -8.2 | — | -6.4 |
| Price/book | 2.9 | 3.8 | 7.1 | -23.4 | 1.2 | 1.5 |
| Dividend yield | — | — | — | — | 0.68% | — |
| 1-year change | −15.24% | +3.50% | +57.48% | +78.66% | +13.08% | −16.77% |
| Today | −3.63% | +1.37% | −1.29% | −2.37% | −0.29% | +2.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PHAR news ›Teva Pharm to grow more in 2027 despite US’ IRA impact on Austedo
JERUSALEM, Nov 3 (Reuters) - Teva Pharmaceutical Industries expects to grow in 2027 despite the US inflation reduction act that will cap prices for its top branded drug Austedo to treat Huntington's Disease and Tardive Dyskinesia,…
Sidley Represents Hanmi Pharm and Green Cross Biopharma in Licensing Agreement With BioMarin
Legal Desire is leading online legal news and insights platform, delivering comprehensive coverage of legal industry news, judgments, legal analysis, law firm updates, career guidance for lawyers, and policy insights. Trusted by legal…
Pharming Leadership Shake-Up Puts Shareholder Disclosure in Focus
This story is AI-assisted. A leadership change needs a stated purpose. Shareholders deserve to know what the board intends it to accomplish, not merely who takes over. On September 29, Pharming Group announced its chief executive’s…
GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin
Business GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin Published : Oct. 30, 2026 - 12:49:01 GC Biopharma and Hanmi Pharmaceutical announced on Friday that they have signed an exclusive licensing-out agreement…
Roche ties help Korea's ST Pharm pursue major RNA CDMO wins
Backed by years of Roche know-how, ST Pharm eyes bigger RNA contracts as demand spreads from rare diseases to obesity Ribonucleic acid (RNA) contract development and manufacturing organizations (CDMO) corporations ST Pharm(75,300 won ▼…
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
Oct 29, 2026, 08:45 ET BioMarin will make an upfront payment of $70 million; GC and Hanmi will be jointly eligible to receive additional payments upon certain development and commercial milestones, and tiered royalties on net sales of…
Maharashtra B Pharmacy, Pharm D Admissions 2026: 29,040 Students Admitted, 14,877 Seats Vacant; Institutional Round Closes Today
The admission process covers the four-year full-time B Pharmacy programme and the six-year full-time Pharm D programme. A total of 47,192 seats across 528 pharmacy colleges were available for the 2026-27 academic session. Students admitted…
Pharming Group (NASDAQ:PHAR) Announces Earnings Results
Posted by Mitch Edgeman on Oct 28th, 2026 Pharming Group (NASDAQ:PHAR – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by…
Pharming Group N.V. 2026 Q3 - Results - Earnings Call Presentation
2026-10-27. The following slide deck was published by Pharming Group N.V. The following slide deck was published by Pharming Group N.V. in conjunction with their 2026 Q3 earnings call. Q3: 2026-10-27 Earnings Summary
Hanmi Pharm Q3 net income down 69.1% to $10.6 mil.
Hanmi Pharm on Tuesday reported a third-quarter net income of 14 billion won ($10.6 million), down 69.1 percent from a year earlier. The Korean pharmaceutical company said in a regulatory filing that operating profit for the July-September…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net3
- seekingalpha.com3
- themarketsdaily.com3
- asiae.co.kr2
- koreatimes.co.kr2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 32 articles, not a forecast.